Ipsen Clinical Trial Pipeline: 34 Active Trials, 16 Changes This Month

10 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 8 with minor changes only.

Notable

LANTIC · IPN10200 · Moderate to Severe Upper Facial Lines

Primary completion pushed from Aug 31, 2026 to Aug 19, 2027

IpsenPhase 1/2 NCT04821089 Registry history of NCT04821089 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Notable

LAURITE 3 · IPN10200 · Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Recruitment opened

Also in this update: Trial sites expanded: 0 → 9 locations

IpsenPhase 3 NCT07779252 Registry history of NCT07779252 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026

Show 8 trials with minor changes only

Minor

LAURITE 2 · IPN10200 Over Time · Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Enrollment closed, study ongoing

IpsenPhase 3 NCT07435428 Registry history of NCT07435428 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

New Medicine Called IPN01195 When Administered Alone · Advanced Solid Tumours

Enrollment closed, study ongoing

Also in this update: Final enrollment: 42 participants (planned 85); Primary and study completion moved earlier from Oct 3, 2028 to Apr 4, 2028

IpsenPhase 1/2 NCT06833008 Registry history of NCT06833008 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

ELFINITY · Observing Everyday Effectiveness and Safety of the Drug Elafibranor · Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Enrollment closed, study ongoing

IpsenNot specified NCT06447168 Registry history of NCT06447168 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

OvEC-PFIC · Odevixibat Outcomes · PFIC Versus an External Control Cohort (OvEC-PFIC)

Primary completion pushed from Sep 21, 2026 to Nov 30, 2026

Also in this update: Completion pushed from Sep 30, 2026 to Nov 30, 2026

IpsenNot specified NCT07497724 Registry history of NCT07497724 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

ELASCOPE · How Well and Safely Elafibranor Works · Primary Sclerosing Cholangitis

Trial sites expanded: 13 → 231 locations

IpsenPhase 3 NCT07387549 Registry history of NCT07387549 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

ELFIDENCE · Elafibranor · Primary Biliary Cholangitis

Trial sites expanded: 186 → 198 locations

IpsenPhase 3 NCT06016842 Registry history of NCT06016842 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

CaboLife · Cabozantinib · Neuroendocrine Tumors Who Have Already Received Prior Treatment

Trial sites expanded: 38 → 41 locations

IpsenNot specified NCT07314164 Registry history of NCT07314164 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

Interventions modified

Also in this update: Trial arms changed: 0 → 1

IpsenNot specified NCT07556913 Registry history of NCT07556913 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Not charted: 14 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 34

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT06016842	A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis	Primary Biliary Cholangitis (PBC)	Recruiting	2026-10-01
NCT07387549	A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With…	Primary Sclerosing Cholangitis	Recruiting	2026-10-01
NCT07779252	A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants…	Moderate to Severe Glabellar Lines	Recruiting	2026-09-14
NCT06730061	A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis…	Primary Biliary Cholangitis	Active, Not Recruiting	2026-10-01
NCT07435428	A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With…	Moderate to Severe Glabellar Lines	Active, Not Recruiting	2026-10-01
NCT07427797	A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to…	Moderate to Severe Glabellar Lines	Active, Not Recruiting	2026-09-09
NCT06047444	A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of…	Chronic Migraine	Active, Not Recruiting	2026-09-04
NCT06047457	A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of…	Episodic Migraine	Active, Not Recruiting	2026-09-04
NCT04526665	Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)	Primary Biliary Cirrhosis	Active, Not Recruiting	2026-09-01
Phase 2/3
NCT07623187	A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With…	Acute Myeloid Leukaemia (AML)	Not Yet Recruiting	2026-09-10
Phase 2
NCT06937931	A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults	Cervical Dystonia	Recruiting	2026-09-08
NCT05627362	A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With…	Primary Sclerosing Cholangitis	Active, Not Recruiting	2026-10-01
NCT06625060	A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic…	Episodic Migraine	Active, Not Recruiting	2026-09-08
Phase 1/2
NCT07213817	A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic…	Locally Advanced Solid Tumor	Recruiting	2026-10-01
NCT07213830	A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics…	Advanced Solid Tumor	Recruiting	2026-09-03
NCT04752774	A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper…	Spasticity	Recruiting	2026-07-28
NCT04821089	A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate…	Moderate to Severe Upper Facial Lines	Active, Not Recruiting	2026-10-06
NCT06305247	A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours	Melanoma	Active, Not Recruiting	2026-09-30
NCT06833008	A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With…	Advanced Solid Tumor	Active, Not Recruiting	2026-09-30
Phase 1
NCT07441707	A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults…	Low-grade Glioma	Active, Not Recruiting	2026-10-01
Not specified
NCT07556913	Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor…	Pregnancy Related	Recruiting	2026-10-06
NCT06089616	A Study to Document and to Further Describe Long-term Safety and Effectiveness of…	Fibrodysplasia Ossificans Progressiva	Recruiting	2026-10-01
NCT06258902	Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety…	Pregnancy Related	Recruiting	2026-10-01
NCT06850038	A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in…	Alagille Syndrome	Recruiting	2026-10-01
NCT07185919	A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With…	Progressive Familial Intrahepatic Cholestasis	Recruiting	2026-10-01

Ipsen clinical trial pipeline

What changed in the last 30 days

LANTIC · IPN10200 · Moderate to Severe Upper Facial Lines

LAURITE 3 · IPN10200 · Moderate to Severe Wrinkle-like Lines Between the Eyebrows

LAURITE 2 · IPN10200 Over Time · Moderate to Severe Wrinkle-like Lines Between the Eyebrows

New Medicine Called IPN01195 When Administered Alone · Advanced Solid Tumours

ELFINITY · Observing Everyday Effectiveness and Safety of the Drug Elafibranor · Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

OvEC-PFIC · Odevixibat Outcomes · PFIC Versus an External Control Cohort (OvEC-PFIC)

ELASCOPE · How Well and Safely Elafibranor Works · Primary Sclerosing Cholangitis

ELFIDENCE · Elafibranor · Primary Biliary Cholangitis

CaboLife · Cabozantinib · Neuroendocrine Tumors Who Have Already Received Prior Treatment

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

Active trials by phase

Active trials top 25 of 34

Disease areas by active trials